All News
RA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read Article
EULAR 2015 Psoriatic Arthritis Treatment Guidelines
The management of psoriatic disease, including psoriatic arthritis (PsA) has evolved significantly in the last decade. Nevertheless, there are still some uncertainties - such as what the role of methotrexate should be, and when to use newer and novel therapies.
Read Article
Drug Safety Update for November 2015
The Down-Side of Electronic Medical Records. EMRs (or EHRs) have become increasingly utilized in daily practice. The benefits of these include better record-keeping, safe prescribing, patient and drug tracking, adverse event monitoring and checks for drug interaction.
Read Article
Microvesicles May Ameliorate Arthritis Damage
Microvesicles are emerging as a new mechanism of intercellular communication by transferring cellular lipid and protein components to target cells, yet their function in disease is only now being explored.
Read Article
The Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read Article
ACP Says There are Reasons for Generics Over Branded Drugs
The American College of Physicians (ACP) says that prescribing generic medications whenever possible can improve adherence to therapy, improve outcomes, and reduce costs for patients and the health care system. ACP’s best practice advice paper is published in Annals of Internal Medicine.
Read Article
EU Endorses Biosimilar Etanercept (SB4) from Samsung/Biogen
Reuters today reported that a copy of the blockbuster biotech drug Enbrel (SB4) was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators.
Read Article
CMS Releases Final Rule on Joint Replacement
MedPage Today reports that the Centers for Medicare & Medicaid Services (CMS) has issued a final rule governing payment for hip and knee replacements for Medicare patients this week that includes several concessions to stakeholders, such as delaying implementation from early 2016 to later in
Read Article
AMA Proposes Ban on Television Drug Ads
The American Medical Association has called for a ban on direct-to-consumer (DTC) advertising for prescription drugs and medical devices, noting these forms of advertising drive up health care costs and often mislead the public.
Read Article
SB4 - A Second Biosimilar Up For Review in Europe
A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.
Read Article
Are Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Pharmacy Benefit Managers at Odds with Specialty Pharmacies
Reuters and the Wall Street Journal have reported that the largest U.S. pharmacy benefit managers (PBM) of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices.
Read Article
Is Baricitinib Really Better Than Adalimumab in RA: Trial Results Reviewed
Dr. Peter Taylor and colleagues presented their results of the 52-week BEAM trial wherein baricitinib (a JAK 1, 2 inhibitor) was compared to adalimumab in both clinical and radiographic outcomes. This was the most viewed abstract online at the ACR website.
Read Article
2015 ACR RA Guidelines Released– Finally!
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read Article
FDA Panel Advises Stronger Warnings on Fluoroquinolones
An FDA Advisory Panel reviewed the safety of fluoroquinolones and their use to treat sinus infections, urinary-tract infections and bronchitis.
Read Article
Increasing Trends for Prescription Drugs, But Not for Arthritis Drugs
JAMA reports the results of trends in drug use in the USA over a 13 year period using data derived 37959 adults survey in the National Health and Nutrition Examination Survey (NHANES).
Read Article
More Adverse Events with Off-Label Drug Use
Off-label use of prescription drugs was associated with adverse drug events in a study of patients in Canada, according to an article published online by JAMA Internal Medicine.
Obamacare Deficient in Rheumatologists, Other Specialists
The October 27 issue of JAMA reports a study of federal marketplace insurance plans shows roughly 15 percent completely lacked in-network physicians for at least one specialty, a practice found among multiple states and issuers.
Read Article
FDA Panel Votes 10-4 to Approve Lesinurad for the Treatment of Hyperuricemia/Gout
Despite concerns over safety, the FDA Arthritis Advisory Committee voted favorably to approve lesinurad (LES) at a meeting held Friday, October 23, 2015. Overall, panel members felt the potential benefits of LES outweighed the safety concerns reviewed by the FDA presenters.
Read Article
Increasing Placebo Responses in the USA
A recent analysis of randomized clincal trials (RCT) for the treatment of neuropathic pain has shown in increase in placebo responses. (Citation source http://buff.ly/1LL8yAi)
Read Article
